Tisbury Pharmaceuticals
Open-angle Glaucoma Treatment
Company Overview
Snapshot
Founded in January 2017 by Andrew Salzman, Tisbury Pharmaceuticals operates with 1–10 employees. The company has raised $32 million across one funding round from 4 investors. In June 2017, the company secured $32 million in its Series A round.
Business overview
Tisbury Pharmaceuticals is a preclinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of treatments for primary open-angle glaucoma. The company's core product, R-801, is a clinical candidate designed to accelerate flow through the trabecular meshwork via redox catalysis and K+-ATP channel activation. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, Tisbury Pharmaceuticals serves the pharmaceutical market in the United States.
Strategic signal
In June 2017, Tisbury Pharmaceuticals successfully raised $32 million, signaling strong investor confidence in its preclinical-stage R-801 candidate for open-angle glaucoma treatment. This significant capital infusion from investors like OrbiMed and Clarus Ventures provided crucial funding for advancing its drug discovery and development efforts, validating the company's approach to addressing a critical unmet medical need in ophthalmology.
Log in to access full profile ›Company Intelligence Q&A
- What is Tisbury Pharmaceuticals' primary focus?
- Tisbury Pharmaceuticals is focused on the discovery, development, and commercialization of treatments for primary open-angle glaucoma.
- When was Tisbury Pharmaceuticals founded?
- Tisbury Pharmaceuticals was founded in January 2017.
- Who is the founder of Tisbury Pharmaceuticals?
- Andrew Salzman is the founder of Tisbury Pharmaceuticals.
- What is the key product of Tisbury Pharmaceuticals?
- Tisbury Pharmaceuticals' key product is R-801, a clinical candidate designed to accelerate flow through the trabecular meshwork for glaucoma treatment.
- What was a significant funding event for Tisbury Pharmaceuticals?
- In June 2017, Tisbury Pharmaceuticals raised $32 million in a Series A funding round from investors including OrbiMed.